Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Kezar Life Sciences, Inc. (KZR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.74-0.03 (-0.34%)
At close: 4:00PM EDT
8.74 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close8.77
Open8.90
Bid8.59 x 1000
Ask9.79 x 1100
Day's Range8.60 - 8.90
52 Week Range4.61 - 9.79
Volume81,429
Avg. Volume259,751
Market Cap421.205M
Beta (5Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KZR

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kezar Life Sciences, Inc.
    Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
    Rating
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • Business Wire

    Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs

    SOUTH SAN FRANCISCO, Calif., October 05, 2021--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of Gitanjali Jain as Vice President, Investor Relations and External Affairs. As a member of the management team and executive committee, Ms. Jain will lead Kezar’s overall investor relations, public relations, and scientific communications effo

  • Business Wire

    Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., September 02, 2021--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in the following upcoming virtual investor conferences:

  • Business Wire

    Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis

    SOUTH SAN FRANCISCO, Calif., August 23, 2021--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that PRESIDIO, its Phase 2 clinical trial to evaluate the safety and efficacy of KZR-616 for the treatment of polymyositis (PM) and dermatomyositis (DM) completed the target enrollment of 24 subjects.

Advertisement
Advertisement